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Rajasekar Thirugnanam, Biju George, Ezhil Chendamarai, Kavitha M. Lakshmi,
Poonkuzhali Balasubramanian, Auro Viswabandya, Alok Srivastava,
Mammen Chandy, Vikram MathewsIn patients with relapsed acute promyelocytic leukemia (APL), the best consolidation regimen following
induction of remission with arsenic trioxide (ATO) remains to be defined. Since January 2000, 37 patients
with relapsed APL were treated at our center. The median age was 34 years (range, 6-57 years), and there
were 20 males (54.1%). The median duration of first remission was 20.3 months (range, 2.9-81.2 months).
Relapse was treated with single-agent ATO in 22 patients (59.5%), ATO1ATRA in 5 patients (13.5%), and
ATO1ATRA1 anthracycline in 10 patients (27%). Thirty-three patients (89%) achievedmolecular remission
after induction and a consolidation course. Fourteen patients opted to undergo autologous stem cell trans-
plantation (SCT), and the remaining 19 patients received monthly cycles of ATO as a single agent (n5 13) or
ATO1ATRA (n5 6) for 6months. At amedian follow-up of 32months, the 5-year Kaplan-Meier estimate of
event-free survival (EFS) was 83.33% 6 15.21% in those who underwent autologous SCT versus 34.45% 6
11.24% in those who did not (P5.001; log-rank test). Following remission induction with ATO-based regi-
mens in patients with relapsed APL, consolidation with autologous SCT is associated with a significantly su-
perior clinical outcome compared with ATO- and ATO1ATRA–based maintenance regimens.
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Despite significant advances in the management of
newly diagnosed cases of acute promyelocytic leukemia
(APL), including the introduction of all-trans-retinoic
acid (ATRA) and arsenic trioxide (ATO), relapses still
occur in 5%-30%of cases [1]. ATOhas proved efficacy
in the management of both newly diagnosed and re-
lapsed APL [2]. It was approved by the U.S. Food and
Drug Administration in September 2000 for the treat-
ment of relapsed and refractory APL. In the setting ofDepartment of Haematology, Christian Medical College,
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in inducing remission, with 80%-90%of relapsed cases
achieving complete hematologic remission (CR). The
majority of those achieving CR also achieve complete
molecular remission (MR) [1].
Retrospective data analysis of adult patients who
had relapsed and were reinduced with an ATRA-based
regimen suggests that in individuals who achieve MR,
autologous stem cell transplantation (SCT) is an effec-
tive mode of consolidation therapy, with an event-free
survival (EFS). 60% [3]. In contrast, allogeneic SCT
is associated with high treatment-related mortality
(TRM) and generally should be reserved for individ-
uals who fail to achieve MR, those who are refractory
to conventional therapy, and possibly those with
a very short duration of first CR [3,4]. However, in
the pediatric population, no significant difference in
clinical outcomes is seen after either allogeneic or
autologous SCT [5].
Most of the available algorithms for managing
relapsed APL are based on data from the ATRA-based1479
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able on the best consolidation regimen for patients
with relapsed APL who have achieved MR with an
ATO-based regimen. Considering ATO’s high effi-
cacy in inducing MR in cases of relapsed APL, as
well as its reported efficacy in inducing durable remis-
sions in newly diagnosed cases with minimal toxicity
either as a single agent or in combinations [6-8], it
would be reasonable to consider further consolidation
with this agent alone or in combination with other
drugs in an attempt to cure the disease without expos-
ing the patient to the risks and morbidity associated
with SCT. However, this approach has never been
validated.
We undertook a retrospective analysis of all cases
of relapsed APL treated at our center to address this
question. At our center, we offer autologous SCT to
all patients with relapsed APL who have achieved
MR after induction and consolidation therapy. Due
to economic constraints, only a proportion of patients
can afford this procedure and the rest opt for the less
expensive consolidation and maintenance with either
single-agent ATO or a combination of ATO and
ATRA.PATIENTS AND METHODS
All patients with APL in first or subsequent relapse
after initial treatment with either a conventional
ATRA-based regimen or ATO, between January
1998 and December 2006, were included in this analy-
sis. These included patients who were initially treated
at other centers and referred to us for further manage-
ment after relapse.
Treatment of Newly Diagnosed APL
After diagnosis of APL, all patients received induc-
tion treatment with either a conventional ATRA-based
regimen [9,10] or up-front single-agent ATO, as we
reported previously [6]. The choice of induction regi-
men was based on economic afford ability and treating
physician’s discretion. Details of therapy for cases ini-
tially treated at other centers were acquired from the
case records of the referring physicians.
Treatment of Relapsed APL
All relapses were confirmed by morphology and
molecular investigations. Only patients who were
positive for t(15;17) by karyotyping, fluorescein in
situ hybridization (FISH), or reverse-transcriptase
polymerase chain reaction (RT-PCR) were included
in this analysis. For remission induction, patients
were treated with single-agent ATO when primary
treatment was ATRA-based or with a combination of
ATRA and ATO, with or without an anthracycline at
the discretion of the treating physician, when the initialtreatment was ATO. All drugs used for remission in-
duction were administered at conventional doses for
up to amaximumof 60 days. Fourweeks after achieving
second or subsequent CR, a consolidation course, sim-
ilar to that used in remission induction, was adminis-
tered for 4 weeks. RT-PCR for PML-RARa, with
a sensitivity of 1 104 fusion transcripts, was done ac-
cording to established protocols to document MR 4
weeks after the completion of consolidation therapy
[11]. Patients who achieved MR were offered autolo-
gous SCT. For those who opted to not undergo autol-
ogous SCT, a maintenance regimen of ATO or
ATO1 ATRA at standard doses was administered
for 10 days/month for 6 months.Autologous SCT
All patients scheduled for autologous SCT under-
went peripheral blood stem cell (PBSC) mobilization
and collection after administration of granulocyte col-
ony-stimulating factor (G-CSF), 10 mg/kg/day for 4
days. This was done only after documentation of MR.
The target CD34 cell dose was of 5 106/kg, which
was to be achieved after 1 or 2 days of apheresis. A min-
imum dose of 2 106/kg was required to proceed with
the SCT. The harvested PBSC product was cryopre-
served.The conditioning regimenconsistedof busulfan
(Bu) 16 mg/kg administered orally over 4 days, fol-
lowed by cyclophosphamide (Cy) administered i.v. at
a dose of 120 mg/kg over 2 days. One day after the
last dose of cyclophosphamide was administered, the
mobilized PBSC product was thawed and rapidly
infused.Definition of Outcomes
Achievement of CR required that a patient have no
clinical evidence of APL, an absolute neutrophil count
(ANC) .1.5 109/L, and unsupported platelet count
of .100 109/L, as well as bone marrow (BM) show-
ing normocellularity to moderate hypocellularity, with
\5% blasts plus promyelocytes. An exception was
made in patients with an ANC \1.5 109/L who
achieved an unsupported platelet count.100 109/L
for more than 2 weeks with no evidence of residual dis-
ease, as defined previously.
Molecular relapse was defined as 2 consecutive
positive RT-PCRs obtained 1 month apart after
achieving MR.
Overall survival (OS) was defined as the time from
initiation of treatment for relapse to last follow-up or
death. EFS was calculated from the time of initiation
of therapy for relapse to last follow-up or an event
(relapse or death). Disease-free survival (DFS) was de-
fined as the time fromachievingCR following induction
therapy for relapse to last follow-upor anevent (relapse).
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The c2 or Fisher’s exact test was used to compare
differences between groups. The probability of sur-
vival was estimated using the product-limit method
of Kaplan-Meier for OS, EFS, and DFS and compared
using the log-rank test. All survival estimates are
reported6 1 standard error. All P values were 2-sided,
with a value of# .05 indicating statistical significance.
All statistical analyses were performed using SPSS
version 11.0 (SPSS Inc, Chicago, IL).RESULTS
Patient Characteristics
Between January 1998 and December 2006, 37
patients (20 males and 17 females) with relapsed APL
were treated at our center. The median age of the pa-
tients was 34 years (range, 6-57 years). The treatment
after the initial diagnosis of APL was conventional
ATRA plus chemotherapy in 23 patients (62.2%) and
single-agent ATO in 14 patients (37.8%). The median
duration of first remission was 20.3 months (range,
2.9-81.2 months). Relapse was isolated medullary in
34 patients (92%), medullary with central nervous sys-
tem (CNS) involvement in 2 patients (5.4%), and iso-
lated CNS in 1 patient.
Thirteen of the 14 patients (93%) in the ATO-based
primary treatmentgroupwere reinducedwitha combina-
tion of ATO and ATRA, with or without an anthracy-
cline. One patient was induced with single-agent ATO.
Thirteen patients (93%) achieved CR (both hematologic
andmolecular) after induction andconsolidation therapy.
The 1 patient who did not achieve CR and died due to
treatment-related complicationswas inducedwitha com-
bination of ATO1 ATRA1 anthracycline.
Twenty of the 23 patients (87%) in the ATRA-based
primary treatment group were reinduced with single-
agent ATO, 2 patients (9%) were induced with
ATO1 ATRA 1 anthracycline, and 1 patient was
induced with ATO 1 mitoxantrone only. Twenty-two
patients (95%) achieved CR after induction, and 19 pa-
tients (83%) achieved MR after the consolidation regi-
men. One patient died of progressive disease while on
induction therapy (reinducedwith ATO1ATRA1 an-
thracycline). Molecular disease persisted at the end of
consolidation in 2 patients (1 each receiving single-agent
ATO and ATO1 ATRA), and, in 1 case, an RT-PCR
was not done at this time point. Four patients relapsed
before further therapy, including the 2 patients with per-
sistent molecular disease and 2 other patients who had
achievedMR. Of these 4 patients, 2 died because of pro-
gressive disease and 2 underwent successful reinduction
therapy and achieved a third CR.
Retinoic acid–like syndrome (RAS) was seen in 4
(10.8%) of the relapsed patients. The symptoms were
usuallymild and resolvedwith administration of a shortcourse of steroids. No mortality could be attributed to
an RAS. No deaths occurred during reinduction be-
cause of bleeding complications. Overall, the bleeding
diathesis was less in this group of patients compared
with newly diagnosed patients treated with similar
protocols (data not shown).
Four patients died before the administration of
consolidation therapy, 1 patient died of treatment-
related complications during induction, and the others
died of progressive disease. The remaining 33 patients
who had achieved MR were offered autologous SCT.
Fourteen patients (42%) opted to undergo autolo-
gous SCT, and the remaining 19 patients (58%)
received 10-days/month cycles of ATO (n5 13) or
ATO1 ATRA (n5 6) for 6 months. The median
age, proportion of males, sites of disease relapse,
and reinduction therapy administered was compara-
ble between the 2 groups, although the duration of
first remission was significantly longer in the group
undergoing autologous SCT (Table 1).
Autologous SCT
All 14 patients who underwent autologous SCT
after achieving MR underwent PBSC mobilization
via administration of G-CSF for 4 days. All patients
received a conditioning regimen consisting of oral Bu
and Cy. The median CD341 cell dose was
9.42 106/kg (range, 3.2-24.3 106/kg). All patients
had documented neutrophil and platelet engraftment.
The median time to neutrophil engraftment was 10
days (range, 9-14 days). All patients developed febrile
neutropenia and grade III/IV mucositis, which was
managed appropriately. No treatment-related deaths
occurred in the first 100 days after transplantation.
One patient had an isolated CNS relapse 5 months
posttransplantation and achieved a third CR following
6 doses of triple intrathecal and cranial radiation ther-
apy (2400 rads in 12 sittings). She subsequently re-
ceived 2 courses (28 days each) of systemic therapy
using ATO. This patient is in continuous CR 36
months after this isolatedCNS relapse. At amedian fol-
low-up of 33 months, the 5-year Kaplan-Meier esti-
mates of OS and EFS for this cohort were 100% 6
0 and 83.33% 6 15.21%, respectively (Figure 1).
ATO-Based Consolidation Regimen
Among the 19 patients who received consolidation
therapy with an ATO-based maintenance regimen
after achieving MR, only 7 (37%) are still alive and in
remission. The remaining 12 patients relapsed again,
at a median time of 12.6 months from the initiation
of therapy for relapse (range, 7.1-29.6 months) and
died of progressive disease at a median of 1.2 months
from relapse (range, 0-42.6 months). In all patients,
the maintenance regimen was administered on an out-
patient basis, and the Eastern Cooperative Oncology
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Figure 1. Outcomeof the 33 patientswith relapsedAPL inCRaccording
to subsequent postremission therapy. A, OS. B, EFS.
Table 1. Comparison of Baseline Characteristics and Clinical
Outcomes of Patients Who Received Consolidation with Au-
tologous SCT versus ThoseConsolidatedwith anATO+ATRA
Regimen
Autologous
SCT (n5 14)
ATO@ + ATRA#
(n5 19) P value
Median age, years (range) 33.0 (10-53) 35.0 (6-57) NS
Sex
Male, n (%) 8 (57.1%) 9 (47.4%) NS
Female, n (%) 6 (42.9%) 10 (52.6%)
Treatment before relapse
ATO@-based 8 (57.1%) 5 (26.3%) NS
ATRA#-based 6 (42.9%) 14 (73.7%)
Site of relapse
Bone marrow 12 (85.7%) 18 (94.7%) NS
Extramedullary 2 (14.3%) 1 (5.3%)
Duration of first CR, months
(range)
23 (5-81) 18 (3-33) .019
Induction therapy for relapse
ATO@ 4 (28.6%) 15 (79.0%) NS
ATO@ +ATRA# 3 (21.4%) 2 (10.5%)
ATO@ +ATRA#
+ anthracycline
7 (50.0%) 2 (10.5%)
RAS during induction
for relapse
2 (14.3%) 2 (10.5%) NS
Consolidation therapy
ATO@ 4 (28.6%) 14 (73.7%) .021
ATO@ +ATRA# 9 (64.3%) 3 (15.8 %)
ATO@ +ATRA#
+ anthracycline
1 (7.1%) 2 (10.5 %)
Status before
SCT/maintenance
CR2 12 19 NS
CR3 2 0
Relapses 1 (7.1%) 12 (63.2%) .000
5-year Kaplan-Meier
estimate of EFS
83.33 ± 15.21 34.45 ± 11.24 .001
5-year Kaplan-Meier
estimate of OS
100.00 ± 00.00 38.50 ± 11.68 .001
NS indicates not significant; SCT, stem cell transplantation; CR, com-
plete remission.
@ATO 5 arsenic trioxide.
#ATRA 5 all-trans retinoic acid.
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None of the patients in this group had any significant
toxicity during administration of the maintenance reg-
imen that required discontinuation or delay of the
scheduled therapy. All patients completed the sched-
uled maintenance regimen. At a median follow-up of
32 months, the 5-year Kaplan-Meier estimates of OS
and EFS for this cohort were 38.5% 6 11.68% and
34.45% 6 11.24%, respectively (Figure 1).
Impact of Additional Factors on Clinical
Outcome
In view of the relatively small number of patients in
the 2 groups and the even smaller number of events,
a formal multivariate analysis was not feasible. In
univariate analysis, neither duration of first remission
nor use of anthracycline in induction following
a relapse was found to have an impact on EFS. In mul-
tivariate analysis using a stepwise forward method
adjusting for age, duration of first remission, and useof anthracyclines in remission induction, only autolo-
gous SCT had a significant impact on EFS. Given
the small number of events, this analysis must be inter-
preted with caution, however. Whereas the median
duration of first remission was significantly longer
(by 5 months) in the group that underwent autologous
SCT, this difference is probably not biologically signif-
icant, as illustrated by the univariate and multivariate
analyses with their limitations. Although the group un-
dergoing autologous SCT had a higher socioeconomic
status, it is unlikely that this was a major factor contrib-
uting to the low relapse risk in this group. In the group
that did not undergo autologous SCT, all patients who
achieved MR completed the scheduled maintenance
regimen. There were no deaths due to regimen related
toxicity or inadequate medical support; rather, the
events were all relapses leading to death, reflecting
the inadequacy of the regimen in these patients.DISCUSSION
The optimal algorithm for managing patients with
relapsed APL who achieve a second remission after
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been established. In view of ATO’s efficacy in inducing
MR in these patients and its proved efficacy, alone or
in combination, in inducing durable remissions in
newly diagnosed cases with minimal toxicity [6-8,12],
it would be reasonable to consider such an ATO-based
combination for consolidation and maintenance ther-
apy and thereby avoid the morbidity and potential
mortality associated with a more intensive consolida-
tion schedule, such as autologous SCT.
Although at our center we offer autologous SCT
for all patients with relapsed APLwho achieve a second
MR, due to financial constraints, only a proportion of
these patients can afford this approach. Thus, we were
able to perform this retrospective analysis of patients
with relapsed APL who underwent consolidation
therapy with either autologous SCT or a combination
of ATO and ATRA. Our experience, as summarized in
this analysis, suggests that all patients with relapsed
APL who achieve MR after therapy with an ATO-
based regimen should be offered autologous SCT.
This approach is associated with excellent clinical
outcomes, as reported here. Although consolidation
and maintenance with an ATO-based regimen is very
well tolerated, the risk of relapse is very high. In
addition, subsequent relapses are difficult to salvage,
with a median time to death from such relapses of
1.2 months.
A limitation of this study is the relatively small
numbers of patients analyzed in a retrospectivemanner
in a single institution. But, nevertheless, our data are
significant, because it is unlikely that a prospective trial
will address this question because of ethical consider-
ations, and because, despite these limitations, the
data suggest superior outcomes from autologous
SCT after achievingMRusing an ATO-based regimen
compared with those from a less-intensive ATO and
ATRA–based maintenance schedule. Compared with
previously reported data for autologous SCT in this
setting [3], the relapse rates reported in the present
analysis appear to be lower, possibly because of the su-
perior quality of MR achieved with an ATO-based
regimen. Similar findings have been noted in another
small study which demonstrated an advantage for pa-
tients who received an ATO based regimen for remis-
sion induction prior to an autologous SCT versus
those who had received an ATRA based regimen
[13]. Large prospective studies are required to address
this issue further.
The risk of relapse in patients with relapsed APL
who received an ATO- or ATO1 ATRA–based main-
tenance regimen after achievingMRwas disappointing
and differed significantly from the outcomes seen in pa-
tients with newly diagnosed APL treated with a single-
agent ATO-based regimen at our center [6]. Clinically,
the incidence and severity of RAS and bleeding diathe-
sis after the initiation of therapy appeared to be lowerthan in newly diagnosed patients, although we were
not able to analyze this systematically because of data-
base limitations. This preliminary observation suggests
that patients with relapsed APL are probably biologi-
cally different from newly diagnosed cases of APL.
Even among those not exposed to ATO at the time of
initial diagnosis, the long-term response rate is signifi-
cantly lower than that achieved in newly diagnosed pa-
tients using the same agent. It is possible that relapsed
patients acquire additional molecular defects that ac-
count for this; however, because most achieve a MR
and subsequently relapse, it is likely that such
molecular events are restricted predominantly to the
leukemia-initiating compartment. Further basic sci-
ence studies are needed to address this issue.
Our data appear to differ from that of an earlier
study comparing the clinical outcomes of relapsed
APL treated with ATO, conventional combination
chemotherapy, or allogeneic SCT [14]. The authors
of that study concluded that treatment with an ATO-
based regimen was superior to conventional combina-
tion chemotherapy or an allogeneic SCT with respect
to OS. They noted the high TRM associated with
combination chemotherapy and an allogeneic SCT,
along with the 100% rate of CR in patients treated
with single-agent ATO. But, even with a relatively
short follow-up, about 40% of the patients receiving
an ATO-based regimen relapsed, although most of
them were salvaged with a combination of ATO and
ATRA, accounting for the superior OS in this arm.
These data are actually consistent with our findings
of high response rate but a subsequent high risk of
relapse in patients treated with only an ATO-based
regimen. However, the results from an ATO-based
regimen reported by that group are superior to those
observed by us, probably because of the significant
higher cumulative anthracycline dose that they used
for induction along with ATO [14]. Our data also
differed in terms of our inability to salvage most of
the cases that did relapse following an ATO-based
reinduction regimen. This was dictated in part by the
inability of most of the cases to proceed with adequate
chemotherapy and support regimens because of
financial constraints. Two other studies with short
follow-up times noted a similar high response rate,
but leukemia-free survivals (LFS) of only 56% and
42% [15,16]. Our data cannot be extended to apply
to patients receiving interventions at molecular re-
lapse; they apply only to patients presenting with frank
hematologic relapse.
In summary, the present study confirms earlier
observations that in patients with relapsed APL, an
ATO-based regimen is well tolerated and associated
with a high response rate. It also establishes that after
the achievement of a molecular response, consolida-
tion with autologous SCT is superior to a maintenance
regimen consisting of ATO and ATRA.
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